Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002-2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of SARS-CoV-2. Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients' sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other. Our results present potential targets for development of drugs and vaccines for SARS-CoV-2.
| Errataetall: |
ErratumIn: Nat Commun. 2021 Apr 1;12(1):2144. - PMID 33795662 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Nature communications - 11(2020), 1 vom: 27. März, Seite 1620 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ou, Xiuyuan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.04.2020 Date Revised 07.12.2022 published: Electronic ErratumIn: Nat Commun. 2021 Apr 1;12(1):2144. - PMID 33795662 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-020-15562-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308070747 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308070747 | ||
| 003 | DE-627 | ||
| 005 | 20231225130939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-020-15562-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1026.xml |
| 035 | |a (DE-627)NLM308070747 | ||
| 035 | |a (NLM)32221306 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ou, Xiuyuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: Nat Commun. 2021 Apr 1;12(1):2144. - PMID 33795662 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002-2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of SARS-CoV-2. Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients' sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other. Our results present potential targets for development of drugs and vaccines for SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
| 650 | 7 | |a Calcium Channels |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a TPCN2 protein, human |2 NLM | |
| 650 | 7 | |a spike glycoprotein, SARS-CoV |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a PIKFYVE protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 650 | 7 | |a Cathepsins |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
| 650 | 7 | |a EC 3.4.15.1 |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Trypsin |2 NLM | |
| 650 | 7 | |a EC 3.4.21.4 |2 NLM | |
| 650 | 7 | |a Cathepsin L |2 NLM | |
| 650 | 7 | |a EC 3.4.22.15 |2 NLM | |
| 700 | 1 | |a Liu, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Xiaobo |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Mi, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Ruixuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jiaxin |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Zichun |e verfasserin |4 aut | |
| 700 | 1 | |a Mu, Zhixia |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jieyong |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Keping |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jianwei |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Zhaohui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 11(2020), 1 vom: 27. März, Seite 1620 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:1 |g day:27 |g month:03 |g pages:1620 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-020-15562-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 1 |b 27 |c 03 |h 1620 | ||